Interleukin-2 Injection for Melanoma Therapy from Canada
Recombinant human IL-2 in single-dose vials for retail, an immunological cytokine stimulating T-cell response in cancer immunotherapy. HTS 3002.15.00.91 applies as it matches chapter note for interleukins as immunological products in measured retail packs.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Provide stability data for shipping; IL-2 degrades above 8°C, risking total loss
• Declare as 'biotech-derived' to support immunological classification
• Watch for reclassification if sold in multi-dose bulk for hospitals